{"title":"Epigenetic Code for Cell Fate During Development and Disease in Human","authors":"Selcen Çelik Uzuner","doi":"10.14744/ejmo.2023.42324","DOIUrl":"https://doi.org/10.14744/ejmo.2023.42324","url":null,"abstract":"DOI: 10.14744/ejmo.2023.42324 EJMO 2023;7(2):95–102","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75009065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.49922
in
{"title":"Association Between ABO Blood Group and Hashimoto Thyroiditis","authors":"","doi":"10.14744/ejmo.2023.49922","DOIUrl":"https://doi.org/10.14744/ejmo.2023.49922","url":null,"abstract":"in","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.34433
I Gede Eka Wiratnaya
Objectives: The aim of bisphosphonate treatment in patients with metastatic bone disease is to prevent metastatic skeletal morbidity and prevent cancer treatment-induced skeletal damage. The classical recommendation of Zoledronic acid treatment is to be given indefinitely as intravenous infusion every 3 to 4 weeks until patients' health deteriorates. Data on zoledronic acid's long-term effectiveness and safety are insufficient, and some recent literatures start to consider 12-weekly administration as a reasonable alternative in order to minimize the adverse effects. Methods: A systematic search was conducted based on PRISMA guideline to identify relevant studies through PubMed, Google Scholar, and Cochrane database. A total of 5 studies (2867 patients) were included, divided into outcome analysis, processed using Review Manager 5.3. Results: The search of electronic databases yielded a total of 299 entries. Five studies were included in the qualitative and quantitative synthesis following the steps of identifying, screening, determining eligibility, eliminating duplicates, and excluding studies. Out of a total of 2.867 patients, 1.427 received ZA for 12 weeks and 1.440 received ZA for 4 weeks, making up the total number of patients included in this meta-analysis. Each trial had a comparable one-year follow-up duration after ZA was given. We discovered that the incidence of adverse effects varied significantly between the two groups. In contrast, there is no statistically significant difference in the rates of SRE, ONJ, renal dysfunction, or death between the two groups. Conclusion: Our systematic review and meta-analysis reveals that 12-week intervals of zoledronic acid is as effective as the standard 4-week interval in terms of skeletal related event, jaw osteonecrosis, renal dysfunction, and mortality rate. However, the standard 4-week intervals led to higher rate of adverse effects.
{"title":"Interval Comparison of Zoledronic Acid Treatment in Patients with Metastatic Bone Disease, Is 4-Weekly or 12-Weekly More Effective?: A Systematic Review and Meta-analysis","authors":"I Gede Eka Wiratnaya","doi":"10.14744/ejmo.2023.34433","DOIUrl":"https://doi.org/10.14744/ejmo.2023.34433","url":null,"abstract":"Objectives: The aim of bisphosphonate treatment in patients with metastatic bone disease is to prevent metastatic skeletal morbidity and prevent cancer treatment-induced skeletal damage. The classical recommendation of Zoledronic acid treatment is to be given indefinitely as intravenous infusion every 3 to 4 weeks until patients' health deteriorates. Data on zoledronic acid's long-term effectiveness and safety are insufficient, and some recent literatures start to consider 12-weekly administration as a reasonable alternative in order to minimize the adverse effects. Methods: A systematic search was conducted based on PRISMA guideline to identify relevant studies through PubMed, Google Scholar, and Cochrane database. A total of 5 studies (2867 patients) were included, divided into outcome analysis, processed using Review Manager 5.3. Results: The search of electronic databases yielded a total of 299 entries. Five studies were included in the qualitative and quantitative synthesis following the steps of identifying, screening, determining eligibility, eliminating duplicates, and excluding studies. Out of a total of 2.867 patients, 1.427 received ZA for 12 weeks and 1.440 received ZA for 4 weeks, making up the total number of patients included in this meta-analysis. Each trial had a comparable one-year follow-up duration after ZA was given. We discovered that the incidence of adverse effects varied significantly between the two groups. In contrast, there is no statistically significant difference in the rates of SRE, ONJ, renal dysfunction, or death between the two groups. Conclusion: Our systematic review and meta-analysis reveals that 12-week intervals of zoledronic acid is as effective as the standard 4-week interval in terms of skeletal related event, jaw osteonecrosis, renal dysfunction, and mortality rate. However, the standard 4-week intervals led to higher rate of adverse effects.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.44908
S. Lin, C. Ren, Jun Chen, Tingting Liu, J. Dang
DOI: 10.14744/ejmo.2023.44908 EJMO 2023;7(2):120–134 Systematic Meta Analysis Cite This Article: Lin S, Ren C, Chen J, Liu T, Dang J. Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. EJMO 2023;7(2):120–134.
{"title":"Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","authors":"S. Lin, C. Ren, Jun Chen, Tingting Liu, J. Dang","doi":"10.14744/ejmo.2023.44908","DOIUrl":"https://doi.org/10.14744/ejmo.2023.44908","url":null,"abstract":"DOI: 10.14744/ejmo.2023.44908 EJMO 2023;7(2):120–134 Systematic Meta Analysis Cite This Article: Lin S, Ren C, Chen J, Liu T, Dang J. Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. EJMO 2023;7(2):120–134.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84968247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.46574
Yili Yang
. Objectives: Our previous study indicated that USP1 inhibitor ML323 downregulated USP1 in colorectal cancer (CRC) cells, but the specific mechanism was still unknown. Methods: CRC cells were lysed for immunoblotting to detect protein expressions. Quantitative real-time PCR was performed to examine mRNA levels. Cycloheximide chase assays were carried out to evaluate the half-life of USP1. Co-immunoprecipitation was used to analyze the polyubiquitination of USP1. Results: USP1 protein stability was enhanced by the proteasome inhibitor MG132 in CRC cells. The wild-type USP1 was upregulated by MG132, but not its catalytic mutant. Additionally, the polyubiquitination of USP1 was enhanced by MG132 as well, which indicated USP1 was degraded through the ubiquitin-proteasome pathway. Meanwhile, we confirmed ML323 downregulated USP1 expression in CRC cells, and cycloheximide chase assay also revealed ML323 reduced USP1 protein stability. Further results showed ML323-induced USP1 downregulation and destabilization were abolished by MG132. Moreover, USP1 protein destabilization was not reversed by the caspase inhibitor Z-VAD, which further suggested ML323-induced USP1 downregulation was not dependent on the effects of cell death in CRC cells. Conclusion: Our results showed USP1 was auto-ubiquitinated, and ML323 destabilized USP1 through the ubiquitin-proteasome pathway in CRC cells, providing a theoretical basis for anti-CRC drugs’ development targeting USP1.
{"title":"The Deubiquitinating Enzyme USP1 is Auto-Ubiquitinated and Destabilized by ML323 in Colorectal Cancer Cells","authors":"Yili Yang","doi":"10.14744/ejmo.2023.46574","DOIUrl":"https://doi.org/10.14744/ejmo.2023.46574","url":null,"abstract":". Objectives: Our previous study indicated that USP1 inhibitor ML323 downregulated USP1 in colorectal cancer (CRC) cells, but the specific mechanism was still unknown. Methods: CRC cells were lysed for immunoblotting to detect protein expressions. Quantitative real-time PCR was performed to examine mRNA levels. Cycloheximide chase assays were carried out to evaluate the half-life of USP1. Co-immunoprecipitation was used to analyze the polyubiquitination of USP1. Results: USP1 protein stability was enhanced by the proteasome inhibitor MG132 in CRC cells. The wild-type USP1 was upregulated by MG132, but not its catalytic mutant. Additionally, the polyubiquitination of USP1 was enhanced by MG132 as well, which indicated USP1 was degraded through the ubiquitin-proteasome pathway. Meanwhile, we confirmed ML323 downregulated USP1 expression in CRC cells, and cycloheximide chase assay also revealed ML323 reduced USP1 protein stability. Further results showed ML323-induced USP1 downregulation and destabilization were abolished by MG132. Moreover, USP1 protein destabilization was not reversed by the caspase inhibitor Z-VAD, which further suggested ML323-induced USP1 downregulation was not dependent on the effects of cell death in CRC cells. Conclusion: Our results showed USP1 was auto-ubiquitinated, and ML323 destabilized USP1 through the ubiquitin-proteasome pathway in CRC cells, providing a theoretical basis for anti-CRC drugs’ development targeting USP1.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81215446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.53477
Xueli Guo
hypoxia and low levels of oxidative stress, [6, 7] can promote cell survival. But excessively activated autophagy can cause cell death. [8, 9] Therefore, autophagy is considered a therapeutic target for ischemic heart disease, but the specific mechanism is still clear. [10, 11] In recent years, the role of autophagy in MI/RI has been paid more and more attention. This paper will review the role of autophagy in MI/RI.
{"title":"The Role of Autophagy in Myocardial Ischemia and Reperfusion","authors":"Xueli Guo","doi":"10.14744/ejmo.2023.53477","DOIUrl":"https://doi.org/10.14744/ejmo.2023.53477","url":null,"abstract":"hypoxia and low levels of oxidative stress, [6, 7] can promote cell survival. But excessively activated autophagy can cause cell death. [8, 9] Therefore, autophagy is considered a therapeutic target for ischemic heart disease, but the specific mechanism is still clear. [10, 11] In recent years, the role of autophagy in MI/RI has been paid more and more attention. This paper will review the role of autophagy in MI/RI.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79002054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.33713
Yang Xu
Objectives: Linked color imaging (LCI) helps to differentiate minor mucosal changes, which can be objectively judged by red–green–blue pixel brightness. However, whether this color analytic model based on pixel brightness can be applied to diagnose Helicobacter pylori infection remains unknown. Methods: Consecutive adult patients with indications and underwent esophagogastroduodenoscopy for the 1 st time were enrolled in the training (n=166) and validation (n=79) set. Demographic and clinical characteristics were recorded. Target region in gastric antrum was pictured before biopsy for rapid urea test, and pixel brightness was calculated by MATLAB software. Results: In training set, 25 patients had H. pylori infection. Pixel brightness for R and B in patients with H. pylori infection was greatly higher than those in patients without H. pylori infection (R: 210.203±27.233 vs. 196.401±29.018, p=0.043; B: 127.621±26.112 vs. 125.334±27.812, p=0.025). At the cut off of R = 210 and B = 127, the specificity and sensitivity were 0.696 and 0.701. In validation set, 10 patients had H. pylori infection and the findings were consistent with those in training set. Conclusion: Color analytic model based on pixel brightness under LCI was useful in diagnosing H. pylori infection in gastric antrum.
目的:联色成像(LCI)有助于区分轻微的粘膜变化，可通过红绿蓝像素亮度客观判断。然而，这种基于像素亮度的颜色分析模型能否应用于幽门螺杆菌感染的诊断仍是未知的。方法:将有适应证且首次行食管胃十二指肠镜检查的连续成年患者纳入训练组(n=166)和验证组(n=79)。记录人口学和临床特征。活检前对胃窦靶区进行快速尿素检测，并通过MATLAB软件计算像素亮度。结果:训练集中有25例患者发生幽门螺杆菌感染。幽门螺杆菌感染患者R、B的像素亮度显著高于未感染患者(R: 210.203±27.233 vs. 196.401±29.018,p=0.043;B: 127.621±26.112 vs. 125.334±27.812,p=0.025)。在R = 210和B = 127的截点处，特异性和敏感性分别为0.696和0.701。验证组中有10例患者存在幽门螺杆菌感染，与训练组结果一致。结论:LCI下基于像素亮度的颜色分析模型可用于胃窦幽门螺杆菌感染的诊断。
{"title":"Linked Color Imaging and Color Analytic Model Based on Pixel Brightness for Diagnosing H. Pylori Infection in Gastric Antrum","authors":"Yang Xu","doi":"10.14744/ejmo.2023.33713","DOIUrl":"https://doi.org/10.14744/ejmo.2023.33713","url":null,"abstract":"Objectives: Linked color imaging (LCI) helps to differentiate minor mucosal changes, which can be objectively judged by red–green–blue pixel brightness. However, whether this color analytic model based on pixel brightness can be applied to diagnose Helicobacter pylori infection remains unknown. Methods: Consecutive adult patients with indications and underwent esophagogastroduodenoscopy for the 1 st time were enrolled in the training (n=166) and validation (n=79) set. Demographic and clinical characteristics were recorded. Target region in gastric antrum was pictured before biopsy for rapid urea test, and pixel brightness was calculated by MATLAB software. Results: In training set, 25 patients had H. pylori infection. Pixel brightness for R and B in patients with H. pylori infection was greatly higher than those in patients without H. pylori infection (R: 210.203±27.233 vs. 196.401±29.018, p=0.043; B: 127.621±26.112 vs. 125.334±27.812, p=0.025). At the cut off of R = 210 and B = 127, the specificity and sensitivity were 0.696 and 0.701. In validation set, 10 patients had H. pylori infection and the findings were consistent with those in training set. Conclusion: Color analytic model based on pixel brightness under LCI was useful in diagnosing H. pylori infection in gastric antrum.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"133 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75701223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.98984
Y. Roosta
,
，
{"title":"The Higher Prevalence of Anemia among Diabetic Patients with Desirable Lipid Profile: A Retrospective Analysis","authors":"Y. Roosta","doi":"10.14744/ejmo.2023.98984","DOIUrl":"https://doi.org/10.14744/ejmo.2023.98984","url":null,"abstract":",","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78425427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.75981
M. Barone
Dear Editor, Notwithstanding often no clinically evident acute pancreatitis findings are found, a serum pancreatic enzyme elevation is found in up to 80% of critically ill patients.[1] In an emergency setting, in fact, the diagnosis of acute pancreatitis can be misleading due to various reasons, hence concomitant patients’ clinical conditions (e.g. hemodynamic instability, mechanical ventilation) and the establishment of rapidly evolving physiopathological mechanisms. Does an enzyme increase justify the diagnosis of pancreatitis? Actually no. Although a three-time greater titer than upper limits represents one of the recognized diagnostic criteria, findings of hyperamylasemia and/or hyperlipasemia could lead to several interpretations, such as the evolution of severe acute pancreatitis, as defined by the Atlanta criteria, pancreatic complications in patients admitted for other pathologies or a mere biochemical increase in the absence of clinical-radiological signs attributable to pancreatic inflammation. Furthermore, the enzymatic titer does not represent a prognostic factor or an index of progression to a necrotic or haemorrhagic state. Although, a diagnosis of acute pancreatitis at onset can established on the basis of an enzymatic increase supported by suggestive clinical findings, the enzymatic dosage cannot be considered predictive of progression, as in case of the C-reactive protein. Furthermore, in the early stages of the disease, the extensive use of diagnostic radiologic investigations (<96 hours) has no role.[2] As reported by Weaver et al.,[3] in a retrospective analysis including 192 emergency patients, 36.45% had hyperamylasemia but none met clinical or radiological criteria for acute pancreatitis. Furthermore, only 9.4% in this cohort was attributable to an increase in the pancreatic serum isoform. The authors therefore concluded by recommending caution in the dosage and interpretation of the titers of serum amylase in critically ill patients. If on the one hand these evidences represent an explicit recommendation for a prompt and exhaustive nosological classification of hyperamylasemia that could mislead to an erroneous diagnosis, on the other they suggest the need for a critical review of the diagnostic criteria of acute pancreatitis where laboratory findings as far as clinical and radiological findings could lead to a reduced diagnostic power in critically ill patients. Mirko Barone,1 Massimo Ippoliti,1 Felice Mucilli1,2
{"title":"Pancreatic Enzymes Elevation and Emergency Setting: Pancreatitis or Not Pancreatitis? That is the Question","authors":"M. Barone","doi":"10.14744/ejmo.2023.75981","DOIUrl":"https://doi.org/10.14744/ejmo.2023.75981","url":null,"abstract":"Dear Editor, Notwithstanding often no clinically evident acute pancreatitis findings are found, a serum pancreatic enzyme elevation is found in up to 80% of critically ill patients.[1] In an emergency setting, in fact, the diagnosis of acute pancreatitis can be misleading due to various reasons, hence concomitant patients’ clinical conditions (e.g. hemodynamic instability, mechanical ventilation) and the establishment of rapidly evolving physiopathological mechanisms. Does an enzyme increase justify the diagnosis of pancreatitis? Actually no. Although a three-time greater titer than upper limits represents one of the recognized diagnostic criteria, findings of hyperamylasemia and/or hyperlipasemia could lead to several interpretations, such as the evolution of severe acute pancreatitis, as defined by the Atlanta criteria, pancreatic complications in patients admitted for other pathologies or a mere biochemical increase in the absence of clinical-radiological signs attributable to pancreatic inflammation. Furthermore, the enzymatic titer does not represent a prognostic factor or an index of progression to a necrotic or haemorrhagic state. Although, a diagnosis of acute pancreatitis at onset can established on the basis of an enzymatic increase supported by suggestive clinical findings, the enzymatic dosage cannot be considered predictive of progression, as in case of the C-reactive protein. Furthermore, in the early stages of the disease, the extensive use of diagnostic radiologic investigations (<96 hours) has no role.[2] As reported by Weaver et al.,[3] in a retrospective analysis including 192 emergency patients, 36.45% had hyperamylasemia but none met clinical or radiological criteria for acute pancreatitis. Furthermore, only 9.4% in this cohort was attributable to an increase in the pancreatic serum isoform. The authors therefore concluded by recommending caution in the dosage and interpretation of the titers of serum amylase in critically ill patients. If on the one hand these evidences represent an explicit recommendation for a prompt and exhaustive nosological classification of hyperamylasemia that could mislead to an erroneous diagnosis, on the other they suggest the need for a critical review of the diagnostic criteria of acute pancreatitis where laboratory findings as far as clinical and radiological findings could lead to a reduced diagnostic power in critically ill patients. Mirko Barone,1 Massimo Ippoliti,1 Felice Mucilli1,2","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84220902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.42506
Yuan Yuan
Objectives: To evaluate the shortterm efficacy and safety of camrelizumab in combination with apatinib for refractory or metastatic oesophageal squamous cell carcinoma
{"title":"Short-Term Efficacy and Safety of Camrelizumab-Based Treatment for Refractory or Metastatic Oesophageal Squamous Cell Carcinoma","authors":"Yuan Yuan","doi":"10.14744/ejmo.2023.42506","DOIUrl":"https://doi.org/10.14744/ejmo.2023.42506","url":null,"abstract":"Objectives: To evaluate the shortterm efficacy and safety of camrelizumab in combination with apatinib for refractory or metastatic oesophageal squamous cell carcinoma","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：